NCT00004408View on ClinicalTrials.gov

Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 1997

Study Completion Date

November 30, 1999

Conditions
Sickle Cell Anemia
Interventions
DRUG

poloxamer 188

Sponsors

Collaborators (1)

CytRx
All Listed Sponsors
collaborator

CytRx

INDUSTRY

lead

Mast Therapeutics, Inc.

INDUSTRY

NCT00004408 - Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease | Biotech Hunter | Biotech Hunter